Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity

BACKGROUND: Bortezomib (Bz) is a proteasome inhibitor that directly targets antibody-producing plasma cells. We recently reported the first randomized control trial that evaluated the effects of Bz in patients with systemic lupus erythematosus (SLE). In that study, we demonstrated that Bz treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Tomoko, Fujii, Hiroshi, Nose, Masato, Kamogawa, Yukiko, Shirai, Tsuyoshi, Shirota, Yuko, Ishii, Tomonori, Harigae, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553803/
https://www.ncbi.nlm.nih.gov/pubmed/28800777
http://dx.doi.org/10.1186/s13075-017-1397-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553803/
https://www.ncbi.nlm.nih.gov/pubmed/28800777
http://dx.doi.org/10.1186/s13075-017-1397-7

Ejemplares similares